In clinical allotransplantation, the long-term efficacy of rapamycin and other mTOR inhibitors has been firmly established, despite the fact that adverse events have been reported, such as the inhibition of wound healing, buccal ulceration, anemia, hyperglycemia, dyslipidemia, and thrombocytopenia [43,60]. This evidence concerns the gene MTOR and anemia.